revoAD: Deep Learning for Alzheimer’s & Parkinson’s Diagnosis
AJAS · 2024 Biomedical and Health Sciences (inferred)
Overview
Alzheimer’s disease (AD) and Parkinson's disease (PD), progressive neurodegenerative conditions, are characterized by neural apoptosis from amyloid beta and α-synuclein oligomeric proliferation overwhelming neural homeostasis. As prevalence rises exponentially, early detection and intervention grow imperative, though systemic obstacles obstruct access. Investigated is advanced machine learning leveraging subtle speech and handwriting (n=18,942) changes to enable affordable screening. Multilayer long short-term memory networks and 3D convolutional neural networks aimed to sensitively discern prodromal indications of dysfunction. Repeated cross-validation, class weights, and tissue-inspired topologies optimized sensitivity across cohort heterogeneity (7 ethnicities; 4 income strata). Terminal validation achieved 96.2% diagnostic precision distinguishing pathology from normal cognition. Rapid mobile application implementation, revoAD, delivers instantaneous screening using embedded AI discerning subtle writing/vocal dysfunction from patient samples (n=50) with 97.6% accuracy, 10-fold efficiency gains over conventional diagnosis. Initial results validate multimodal deep learning’s potential to enable scalable detection, catalyzing a shift toward presymptomatic precision medicine for unrelenting neurocognitive disorders. Expanding access for marginalized groups is urged, as contemporary systemic barriers obstruct status quo diagnosis. Immediate next phases encompass pragmatic clinical trials and rapid product deployment to mitigate alarming prevalence increases. While promising for earlier intervention, continued methodological vetting across expanded heterogeneous populations remains vital to substantiate external validity claims and qualify appropriate clinical integration benefiting multiplied constituencies through enhanced access.
Competition history
- AJAS 2024
Related projects
ISEF · 2024
PoDE - A Platform Leveraging Characteristic Time Series Patterns of Oculomotor Control Attributable to Cholinergic Neuron Destruction in the Parietal Lobe, Indicating Early Alzheimer's Disease Utilizing the PoDE Neural Network
ISEF · 2024
Alzheimer's Recognition Using Artificial Intelligence
CWSF · 2026
AD-istics: A Machine Learning Framework for Optimized Detection of Dementia and Alzheimer's Disease
ISEF · 2020
Developing a Pre-Risk Assessment Incorporating Machine-Learning and Biomarkers to Diagnose Alzheimer's Disease
ISEF · 2021
PANDwriting: An Accessible Parkinson's and Alzheimer's Novel Diagnostic Framework Using Vision-Based Handwriting Kinematic Analysis and Machine Learning
ISEF · 2022
PANDwriting: An Accessible, High-Sensitivity Parkinson's and Alzheimer's Screening System Using Vision-Based Handwriting Kinematic Analysis and Machine Learning
ISEF · 2026
A Multi-Modal AI/ML Platform for Neurodegenerative Risk Prediction: Integrating Epigenetic Signatures Through cfDNA Methylation and Functional Mobility Data
ISEF · 2022
NeuraHealth: An Automated Screening Pipeline To Detect Undiagnosed Cognitive Impairment in Electronic Health Records Using Deep Learning and Natural Language Processing
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: AAAS Annual Meeting (Confex) / American Junior Academy of Science